Oramed Initiates Phase I Oral GLP-1 Study Under IND

JERUSALEM, Jan. 22, 2019 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 capsule. This is the first study of ORMD-0901 under Oramed’s […]

Join our mailing list

Skip to content